Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Buy These 7 Dividend Stocks and Hold Forever
10:10am, Tuesday, 02'nd Jul 2024
24/7 Insights Quality dividend stocks outperform non-dividend stocks for shareholders.
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
09:45am, Tuesday, 02'nd Jul 2024
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
What's Next For Elanco Stock After Its Recent 20% Drop?
08:00am, Monday, 01'st Jul 2024
The stock price of Elanco (NYSE: ELAN), an animal health products company, saw a 20% fall on Thursday, June 27, after the company announced a delay in expected approval of two drugs. In comparison, Me
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
06:30am, Monday, 01'st Jul 2024
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
02:00pm, Friday, 28'th Jun 2024
In a portfolio, it's generally growth stocks that grab the limelight. Being high-beta stocks, the price action keeps investors on the edge.
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
08:31am, Friday, 28'th Jun 2024
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Bioreactors Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Fabrication Material, Type of Bioprocess, Type of Biologic, and Key
Merck Stock Is Slipping. A CDC Committee Considers Pneumococcal Vaccines.
02:21pm, Thursday, 27'th Jun 2024
News out of a Centers for Disease Control and Prevention meeting appeared to dim the commercial prospects of Merck's new pneumococcal vaccine.
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
11:25am, Thursday, 27'th Jun 2024
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
06:42am, Thursday, 27'th Jun 2024
The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided mi
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
07:45pm, Wednesday, 26'th Jun 2024
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking acceler
Healthcare: Best strategies to invest in pharma stocks
11:55am, Wednesday, 26'th Jun 2024
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today t
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
02:39pm, Tuesday, 25'th Jun 2024
Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
China grants licence to Merck's KEYTRUDA for stomach cancer treatment
07:08am, Tuesday, 25'th Jun 2024
China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
